View : 289 Download: 0

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)

Title
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)
Authors
Lee, Jung-YunPark, Jeong-YeolPark, Sang YoonLee, Jeong-WonKim, Jae WeonKim, Yong BeomJeong, Dae HoonLee, Kwang-BeomKim, Tae-HunLee, In HoChoi, Min ChulKim, Ki HyungKim, Yong-ManLee, Yong JaeKang, SokbomPujade-Lauraine, EricShin, So-JinHong, Dae GyShim, Seung-HyukKim, Yun HwanSong, TaejongBae, JaemanLee, Jong-MinLee, San HuiLee, Eun-JuPark, Sang-IlLee, Sung-JongLee, ChulminLee, Taek SangChang, Suk-JoonKim, Min KyuKGOG Investigators
Ewha Authors
김윤환
SCOPUS Author ID
김윤환scopus
Issue Date
2019
Journal Title
GYNECOLOGIC ONCOLOGY
ISSN
0090-8258JCR Link

1095-6859JCR Link
Citation
GYNECOLOGIC ONCOLOGY vol. 152, no. 1, pp. 61 - 67
Keywords
Ovarian cancerPlatinum-resistantBevacizumabChemotherapyReal world
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Indexed
SCIE; SCOPUS WOS
Document Type
Article

Proceedings Paper
Abstract
Purpose. To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum resistant ovarian cancer in a real-world setting. Patients and methods. We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. Results. Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade >= 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. Conclusion. In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. (C) 2018 Elsevier Inc. All rights reserved.
Show the fulltext
DOI
10.1016/j.ygyno.2018.10.031
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE